PDCD1 and neoplasm: Although both F1/F3 plus anti-PD-1 and F1/F3 alone were able to delay tumor progression, there was no statistically significant difference between the two regimens; the median survival times of mice in the F1/F3 plus anti-PD-1 group and the F1/F3-alone group were 38 and 40 days, respectively (Figure S3A–C).